Applied therapeutics to present on diabetic cardiomyopathy and prevalence of disease at the 81st scientific sessions of the 2021 annual meeting of the american diabetes association

New york, june 21, 2021 (globe newswire) -- applied therapeutics, inc. (nasdaq: aplt), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced a product theater presentation at the upcoming 81st scientific sessions of the annual 2021 american diabetes association meeting taking place virtually june 25-29. the product theater will include an overview of diabetic cardiomyopathy (dbcm), the increased risk of progression to overt heart failure and death due to the disease, new data on the wide prevalence of the disease among patients with diabetes, the role of aldose reductase in the pathogenesis of disease, and a review of the ongoing arise-hf global registrational trial of at-001, a novel and selective aldose reductase inhibitor.
APLT Ratings Summary
APLT Quant Ranking